Associate professor

University of Maryland Surgical Team Who Conducted Historic Xenotransplantation to Speak in Plenary Session at HFSA Annual Scientific Meeting 2022

Retrieved on: 
Thursday, August 11, 2022 - 2:15pm

The patient survived for two months following the first-of-its-kind surgery, which was performed at the University of Maryland Medical Center.

Key Points: 
  • The patient survived for two months following the first-of-its-kind surgery, which was performed at the University of Maryland Medical Center.
  • The results of this groundbreaking xenotransplant surgery will be discussed in detail during the Monday Plenary Session Cardiac Xenotransplantation: Where we are and where we are going at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) on Monday, October 3, 2022.
  • The HFSA Annual Scientific Meeting will take place September 30-October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.
  • This year's meeting will include three plenary sessions , held in the mornings to kick-off each day of programming.

IMV Inc. Announces Second Quarter 2022 Financial and Operational Results

Retrieved on: 
Thursday, August 11, 2022 - 12:05pm

IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.

Key Points: 
  • IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.
  • IMV continues to enroll patients in the VITALIZE Phase 2B clinical trial, advancing its lead compound, maveropepimut-S (MVP-S) in a global, multi-center confirmatory trial.
  • IMV is on track to complete enrollment of the first stage of the study in H1 2023.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Capella Space Unveils Next Generation Satellite with Enhanced Imagery Capabilities and Communication Features

Retrieved on: 
Wednesday, August 10, 2022 - 2:00pm

SAN FRANCISCO, Aug. 10, 2022 /PRNewswire/ -- Capella Space, a leading Earth observation company, today unveiled several new capabilities planned for its next generation satellites, further expanding the company's cutting-edge, premium data offerings. This new generation of Capella satellites, referred to as "Acadia" technology, will expand the existing Capella constellation to provide highest quality imagery, best ground-range resolution, and the fastest order-to-delivery speeds available from any commercial SAR provider.

Key Points: 
  • This new generation of Capella satellites, referred to as "Acadia" technology, will expand the existing Capella constellation to provide highest quality imagery, best ground-range resolution, and the fastest order-to-delivery speeds available from any commercial SAR provider.
  • Highest quality imagery with increased power: Capella customers are already accustomed to Capella's high quality SAR imagery.
  • Fastest order-to-delivery with improved payload downlink: Capella has already pioneered the usage of GEO communication satellites for near real-time tasking of its satellites.
  • Capella Space is an information services company that provides on-demand, industry-leading, high-resolution synthetic aperture radar (SAR) Earth observation imagery.

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors

Retrieved on: 
Tuesday, August 9, 2022 - 2:00pm

In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.

Key Points: 
  • In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.
  • The myCare-203A study found that the personalized approach of Cellworks Singula TRI produces a more precise therapeutic decision guide for patients with NSCLC.
  • The myCare-203A study shows us that the Cellworks Biosimulation Platform and Singula TRI can streamline the treatment decision-making process and improve NSCLC patient outcomes through personalized therapy response predictions.
  • These results show that physicians can use Cellworks Singula TRI scores to more precisely guide therapeutic decisions for individual patients with NSCLC.

Point-of-Care Ultrasound Certification Academy to Host World Conference

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

ROCKVILLE, Md., Aug. 8, 2022 /PRNewswire/ -- The global point-of-care ultrasound (POCUS) community, consisting of numerous specialties of healthcare providers, will gather virtually to expand and share their knowledge and experience with ultrasound at POCUS World Conference 2022 on September 16-17. Sponsored by Inteleos™, a non-profit community of medical professionals united in helping people gain the highest quality healthcare, the virtual conference will feature speakers from around the world to share best practices in POCUS education, application and certification.

Key Points: 
  • The theme for this year's conference is Imaging as Innovation: Transforming Patient Care Through Point-of-Care Ultrasound.
  • POCUS World 2022 attendees will have access to multiple learning and collaboration opportunities, including:
    Networking opportunities through participating in a global POCUS community event.
  • "The POCUS Certification Academy and Inteleos are committed to expanding the knowledge and practical application of point-of-care ultrasound around the world.
  • Inteleos is the overarching governance and management organization for the American Registry for Diagnostic Medical Sonography ( ARDMS ) the Alliance for Physician Certification & Advancement ( APCA ) and the Point-of-Care Ultrasound Certification Academy ( POCUS ) which together represents over 124,000 certified medical professionals throughout the world.

Point-of-Care Ultrasound Certification Academy to Host World Conference

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

ROCKVILLE, Md., Aug. 8, 2022 /PRNewswire/ -- The global point-of-care ultrasound (POCUS) community, consisting of numerous specialties of healthcare providers, will gather virtually to expand and share their knowledge and experience with ultrasound at POCUS World Conference 2022 on September 16-17. Sponsored by Inteleos™, a non-profit community of medical professionals united in helping people gain the highest quality healthcare, the virtual conference will feature speakers from around the world to share best practices in POCUS education, application and certification.

Key Points: 
  • The theme for this year's conference is Imaging as Innovation: Transforming Patient Care Through Point-of-Care Ultrasound.
  • POCUS World 2022 attendees will have access to multiple learning and collaboration opportunities, including:
    Networking opportunities through participating in a global POCUS community event.
  • "The POCUS Certification Academy and Inteleos are committed to expanding the knowledge and practical application of point-of-care ultrasound around the world.
  • Inteleos is the overarching governance and management organization for the American Registry for Diagnostic Medical Sonography ( ARDMS ) the Alliance for Physician Certification & Advancement ( APCA ) and the Point-of-Care Ultrasound Certification Academy ( POCUS ) which together represents over 124,000 certified medical professionals throughout the world.

Klaytn Spearheads World's Largest Blockchain Research Center Program in Collaboration with Top-Ranking Universities KAIST and NUS

Retrieved on: 
Monday, August 8, 2022 - 10:29am

BRC is a virtual research institute that aims to advance cutting-edge research for blockchain technology, deepen blockchain capabilities, and support industry growth.

Key Points: 
  • BRC is a virtual research institute that aims to advance cutting-edge research for blockchain technology, deepen blockchain capabilities, and support industry growth.
  • With a US$20m funding commitment from Klaytn over the next four years, BRC is to date the world's largest blockchain research center program in terms of known funding size.
  • Through our BRC program, in collaboration with leading minds from KAIST and NUS, we are delighted to take the next step in bringing our vision to life."
  • Dr Kang said, "Our world-class blockchain researchers at the Blockchain Research Center will contribute to the seven pillars of blockchain research: consensus, privacy, network, smart contracts, DeFi, economics/ethics, and metaverse.

The 37th Edition of World AI Show Addressed the Necessity of Boosting AI Adoption in Malaysia

Retrieved on: 
Friday, August 5, 2022 - 9:30am

Trescon, the event's host, brought together more than 250 online participants, including important players in Malaysia's AI ecosystem like government officials, leading AI specialists, and solution vendors.

Key Points: 
  • Trescon, the event's host, brought together more than 250 online participants, including important players in Malaysia's AI ecosystem like government officials, leading AI specialists, and solution vendors.
  • Leading players in AI & Data space like Dataiku | Strateq, Denodo, Alteryx, TigerGraph, ServiceNow, ManageEngine and Snowflake gathered at the virtual conference to examine the prospects for AI in Malaysia.
  • Judy Nam, Principal Solutions Engineer Director, Dataiku spoke at length of "Defining a Successful AI Project: A Framework for Choosing the Right AI Use Case."
  • "Since AI brings up a wide range of possibilities, finding the correct business context for it is critical to achieving success.

Natural Killer Cells: Progress and Promise, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, July 28, 2022 - 1:30pm

TORONTO, July 28, 2022 /PRNewswire-PRWeb/ -- Natural killer (NK) cells have moved front and center as one of the most exciting therapeutic technologies in clinical development. They are considered by many experts to be a critical cell type in the fight against solid tumors.

Key Points: 
  • TORONTO, July 28, 2022 /PRNewswire-PRWeb/ -- Natural killer (NK) cells have moved front and center as one of the most exciting therapeutic technologies in clinical development.
  • The goal of this webinar is to provide a complete view of the progress being made in NK cell therapies alongside the promise and challenges they present as they move into the clinic.
  • For more information, or to register for this event, visit Natural Killer Cells: Progress and Promise.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Chemotherapy Drugs from "Rogue" Online Pharmacies Could Endanger Leukemia Patients, Suggests Research in JNCCN

Retrieved on: 
Thursday, July 28, 2022 - 1:12pm

PLYMOUTH MEETING, Pa., July 28, 2022 /PRNewswire/ -- Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network. A survey of online pharmacies claiming to sell the oral chemotherapy drug imatinib found that only three of the 44 identified English-language sites that shipped within the United States were certified through the LegitScript online pharmacy monitoring service. A full 52% were classified as "rogue" pharmacies that might operate without a license, sell counterfeit or expired products, steal users' payment information, or reject important safety precautions like requiring a prescription for potentially hazardous medications. 

Key Points: 
  • A new study finds a majority of online pharmacies selling the chronic myeloid leukemia therapy imatinib are uncertified and could be operating unsafely.
  • Tyrosine kinase inhibitors like imatinib have made chronic myeloid leukemia (CML) a manageable condition rather than a fatal one.
  • Yet to work optimally, the drug must be taken for the rest of a patient's life and with high compliance.
  • Complimentary access to " Online Pharmacy Accessibility of Imatinib, An Oral Chemotherapy Medication " is available until October 10, 2022.